Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-02-08
2005-02-08
Wilson, James O. (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S045000, C536S027220, C536S026130, C536S027300, C536S027620, C536S022100, C536S026600, C252S299630, C546S296000, C548S311100
Reexamination Certificate
active
06852746
ABSTRACT:
The present invention relates to a crystalline form of 6-[(2,2-diphenylethyl)amino]-9-(N-ethyl-β-D-ribofuranosyluronamide)-N-(2-{N′-[1-(2-pyridyl)-4-piperidyl]ureido}ethyl)-9H-purine-2-carboxamide and to a process for the preparation of, compositions containing and the uses of such a crystalline form.
REFERENCES:
patent: 5593975 (1997-01-01), Cristalli
patent: WO 9111172 (1991-08-01), None
patent: WO 9402518 (1994-02-01), None
patent: WO 9855148 (1998-12-01), None
patent: WO 0077018 (2000-12-01), None
patent: WO 0120089 (2001-03-01), None
patent: WO 0160835 (2001-08-01), None
patent: WO 0194368 (2001-12-01), None
patent: WO 0209462 (2002-12-01), None
Silk Terence Vernon
Smith Julian Duncan
Benson Gregg C.
Khare Devesh
Mulholland William F.
Pfizer Inc
Richardson Peter C.
LandOfFree
Crystalline drug form does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Crystalline drug form, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Crystalline drug form will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3476003